Log in

NYSE:BCSFBain Capital Specialty Finance Competitors & Alternatives

$10.34
+0.13 (+1.27 %)
(As of 07/10/2020 04:00 PM ET)
Add
Compare
Today's Range
$10.04
Now: $10.34
$10.38
50-Day Range
$10.11
MA: $11.26
$13.01
52-Week Range
$7.11
Now: $10.34
$20.35
Volume231,000 shs
Average Volume247,916 shs
Market Capitalization$534.06 million
P/E RatioN/A
Dividend Yield16.06%
Beta1.6

Competitors

Bain Capital Specialty Finance (NYSE:BCSF) Vs. VRRM, AHCO, GSAH, HYAC, FMCI, and CO

Should you be buying BCSF stock or one of its competitors? Companies in the industry of "holding & other investment offices" are considered alternatives and competitors to Bain Capital Specialty Finance, including Verra Mobility (VRRM), AdaptHealth (AHCO), GS ACQUISITION /SH CL A (GSAH), HAYMAKER ACQUIS/SH CL A (HYAC), FORUM MERGER II/SH CL A (FMCI), and Global Cord Blood (CO).

Verra Mobility (NASDAQ:VRRM) and Bain Capital Specialty Finance (NYSE:BCSF) are both small-cap industrial products companies, but which is the better business? We will compare the two businesses based on the strength of their analyst recommendations, dividends, earnings, risk, valuation, institutional ownership and profitability.

Analyst Ratings

This is a breakdown of current ratings and recommmendations for Verra Mobility and Bain Capital Specialty Finance, as provided by MarketBeat.com.

Sell RatingsHold RatingsBuy RatingsStrong Buy RatingsRating Score
Verra Mobility01602.86
Bain Capital Specialty Finance16102.00

Verra Mobility currently has a consensus price target of $13.50, indicating a potential upside of 37.20%. Bain Capital Specialty Finance has a consensus price target of $12.1429, indicating a potential upside of 17.44%. Given Verra Mobility's stronger consensus rating and higher probable upside, research analysts clearly believe Verra Mobility is more favorable than Bain Capital Specialty Finance.

Volatility & Risk

Verra Mobility has a beta of 1.52, meaning that its stock price is 52% more volatile than the S&P 500. Comparatively, Bain Capital Specialty Finance has a beta of 1.6, meaning that its stock price is 60% more volatile than the S&P 500.

Insider & Institutional Ownership

91.3% of Verra Mobility shares are held by institutional investors. Comparatively, 52.2% of Bain Capital Specialty Finance shares are held by institutional investors. 0.9% of Verra Mobility shares are held by insiders. Comparatively, 0.4% of Bain Capital Specialty Finance shares are held by insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a company is poised for long-term growth.

Earnings & Valuation

This table compares Verra Mobility and Bain Capital Specialty Finance's revenue, earnings per share (EPS) and valuation.

Gross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Verra Mobility$416.72 million3.82$33.34 million$0.6515.14
Bain Capital Specialty Finance$197.95 million2.70$98.08 million$1.646.30

Bain Capital Specialty Finance has lower revenue, but higher earnings than Verra Mobility. Bain Capital Specialty Finance is trading at a lower price-to-earnings ratio than Verra Mobility, indicating that it is currently the more affordable of the two stocks.

Profitability

This table compares Verra Mobility and Bain Capital Specialty Finance's net margins, return on equity and return on assets.

Net MarginsReturn on EquityReturn on Assets
Verra Mobility7.97%35.20%8.45%
Bain Capital Specialty Finance-21.80%8.72%3.26%

Summary

Verra Mobility beats Bain Capital Specialty Finance on 11 of the 14 factors compared between the two stocks.

AdaptHealth (NASDAQ:AHCO) and Bain Capital Specialty Finance (NYSE:BCSF) are both small-cap medical companies, but which is the better stock? We will compare the two companies based on the strength of their dividends, institutional ownership, analyst recommendations, profitability, valuation, earnings and risk.

Profitability

This table compares AdaptHealth and Bain Capital Specialty Finance's net margins, return on equity and return on assets.

Net MarginsReturn on EquityReturn on Assets
AdaptHealthN/A-14.40%0.41%
Bain Capital Specialty Finance-21.80%8.72%3.26%

Analyst Ratings

This is a breakdown of current ratings for AdaptHealth and Bain Capital Specialty Finance, as provided by MarketBeat.

Sell RatingsHold RatingsBuy RatingsStrong Buy RatingsRating Score
AdaptHealth00503.00
Bain Capital Specialty Finance16102.00

AdaptHealth currently has a consensus price target of $19.80, suggesting a potential upside of 5.32%. Bain Capital Specialty Finance has a consensus price target of $12.1429, suggesting a potential upside of 17.44%. Given Bain Capital Specialty Finance's higher probable upside, analysts clearly believe Bain Capital Specialty Finance is more favorable than AdaptHealth.

Risk & Volatility

AdaptHealth has a beta of -0.17, indicating that its share price is 117% less volatile than the S&P 500. Comparatively, Bain Capital Specialty Finance has a beta of 1.6, indicating that its share price is 60% more volatile than the S&P 500.

Earnings & Valuation

This table compares AdaptHealth and Bain Capital Specialty Finance's top-line revenue, earnings per share and valuation.

Gross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
AdaptHealth$529.64 million1.64$-15,000,000.00$0.3062.67
Bain Capital Specialty Finance$197.95 million2.70$98.08 million$1.646.30

Bain Capital Specialty Finance has lower revenue, but higher earnings than AdaptHealth. Bain Capital Specialty Finance is trading at a lower price-to-earnings ratio than AdaptHealth, indicating that it is currently the more affordable of the two stocks.

Institutional & Insider Ownership

53.9% of AdaptHealth shares are held by institutional investors. Comparatively, 52.2% of Bain Capital Specialty Finance shares are held by institutional investors. 10.9% of AdaptHealth shares are held by insiders. Comparatively, 0.4% of Bain Capital Specialty Finance shares are held by insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a company is poised for long-term growth.

Bain Capital Specialty Finance (NYSE:BCSF) and GS ACQUISITION /SH CL A (NYSE:GSAH) are both small-cap finance companies, but which is the better investment? We will contrast the two businesses based on the strength of their institutional ownership, risk, valuation, analyst recommendations, dividends, earnings and profitability.

Valuation and Earnings

This table compares Bain Capital Specialty Finance and GS ACQUISITION /SH CL A's gross revenue, earnings per share (EPS) and valuation.

Gross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Bain Capital Specialty Finance$197.95 million2.70$98.08 million$1.646.30
GS ACQUISITION /SH CL AN/AN/A$5.03 millionN/AN/A

Bain Capital Specialty Finance has higher revenue and earnings than GS ACQUISITION /SH CL A.

Institutional and Insider Ownership

52.2% of Bain Capital Specialty Finance shares are held by institutional investors. Comparatively, 46.7% of GS ACQUISITION /SH CL A shares are held by institutional investors. 0.4% of Bain Capital Specialty Finance shares are held by insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a stock is poised for long-term growth.

Analyst Ratings

This is a summary of current ratings and recommmendations for Bain Capital Specialty Finance and GS ACQUISITION /SH CL A, as provided by MarketBeat.

Sell RatingsHold RatingsBuy RatingsStrong Buy RatingsRating Score
Bain Capital Specialty Finance16102.00
GS ACQUISITION /SH CL A0000N/A

Bain Capital Specialty Finance currently has a consensus price target of $12.1429, indicating a potential upside of 17.44%. Given Bain Capital Specialty Finance's higher possible upside, research analysts plainly believe Bain Capital Specialty Finance is more favorable than GS ACQUISITION /SH CL A.

Risk & Volatility

Bain Capital Specialty Finance has a beta of 1.6, suggesting that its stock price is 60% more volatile than the S&P 500. Comparatively, GS ACQUISITION /SH CL A has a beta of 0.07, suggesting that its stock price is 93% less volatile than the S&P 500.

Profitability

This table compares Bain Capital Specialty Finance and GS ACQUISITION /SH CL A's net margins, return on equity and return on assets.

Net MarginsReturn on EquityReturn on Assets
Bain Capital Specialty Finance-21.80%8.72%3.26%
GS ACQUISITION /SH CL AN/A198.32%1.41%

Summary

Bain Capital Specialty Finance beats GS ACQUISITION /SH CL A on 8 of the 11 factors compared between the two stocks.

HAYMAKER ACQUIS/SH CL A (NASDAQ:HYAC) and Bain Capital Specialty Finance (NYSE:BCSF) are both small-cap unclassified companies, but which is the better investment? We will compare the two businesses based on the strength of their institutional ownership, analyst recommendations, dividends, profitability, risk, earnings and valuation.

Analyst Recommendations

This is a breakdown of recent ratings and price targets for HAYMAKER ACQUIS/SH CL A and Bain Capital Specialty Finance, as reported by MarketBeat.com.

Sell RatingsHold RatingsBuy RatingsStrong Buy RatingsRating Score
HAYMAKER ACQUIS/SH CL A0000N/A
Bain Capital Specialty Finance16102.00

Bain Capital Specialty Finance has a consensus target price of $12.1429, indicating a potential upside of 17.44%. Given Bain Capital Specialty Finance's higher possible upside, analysts plainly believe Bain Capital Specialty Finance is more favorable than HAYMAKER ACQUIS/SH CL A.

Valuation & Earnings

This table compares HAYMAKER ACQUIS/SH CL A and Bain Capital Specialty Finance's top-line revenue, earnings per share (EPS) and valuation.

Gross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
HAYMAKER ACQUIS/SH CL AN/AN/AN/AN/AN/A
Bain Capital Specialty Finance$197.95 million2.70$98.08 million$1.646.30

Bain Capital Specialty Finance has higher revenue and earnings than HAYMAKER ACQUIS/SH CL A.

Insider and Institutional Ownership

56.5% of HAYMAKER ACQUIS/SH CL A shares are held by institutional investors. Comparatively, 52.2% of Bain Capital Specialty Finance shares are held by institutional investors. 0.4% of Bain Capital Specialty Finance shares are held by insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a company will outperform the market over the long term.

Profitability

This table compares HAYMAKER ACQUIS/SH CL A and Bain Capital Specialty Finance's net margins, return on equity and return on assets.

Net MarginsReturn on EquityReturn on Assets
HAYMAKER ACQUIS/SH CL AN/AN/AN/A
Bain Capital Specialty Finance-21.80%8.72%3.26%

Summary

Bain Capital Specialty Finance beats HAYMAKER ACQUIS/SH CL A on 6 of the 8 factors compared between the two stocks.

FORUM MERGER II/SH CL A (NASDAQ:FMCI) and Bain Capital Specialty Finance (NYSE:BCSF) are both small-cap unclassified companies, but which is the better investment? We will compare the two businesses based on the strength of their dividends, profitability, valuation, risk, institutional ownership, earnings and analyst recommendations.

Profitability

This table compares FORUM MERGER II/SH CL A and Bain Capital Specialty Finance's net margins, return on equity and return on assets.

Net MarginsReturn on EquityReturn on Assets
FORUM MERGER II/SH CL AN/A1.86%0.05%
Bain Capital Specialty Finance-21.80%8.72%3.26%

Insider and Institutional Ownership

70.0% of FORUM MERGER II/SH CL A shares are held by institutional investors. Comparatively, 52.2% of Bain Capital Specialty Finance shares are held by institutional investors. 21.7% of FORUM MERGER II/SH CL A shares are held by insiders. Comparatively, 0.4% of Bain Capital Specialty Finance shares are held by insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a company is poised for long-term growth.

Volatility & Risk

FORUM MERGER II/SH CL A has a beta of 0.23, indicating that its stock price is 77% less volatile than the S&P 500. Comparatively, Bain Capital Specialty Finance has a beta of 1.6, indicating that its stock price is 60% more volatile than the S&P 500.

Analyst Recommendations

This is a breakdown of recent ratings for FORUM MERGER II/SH CL A and Bain Capital Specialty Finance, as provided by MarketBeat.

Sell RatingsHold RatingsBuy RatingsStrong Buy RatingsRating Score
FORUM MERGER II/SH CL A0000N/A
Bain Capital Specialty Finance16102.00

Bain Capital Specialty Finance has a consensus target price of $12.1429, indicating a potential upside of 17.44%. Given Bain Capital Specialty Finance's higher probable upside, analysts plainly believe Bain Capital Specialty Finance is more favorable than FORUM MERGER II/SH CL A.

Earnings and Valuation

This table compares FORUM MERGER II/SH CL A and Bain Capital Specialty Finance's revenue, earnings per share and valuation.

Gross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
FORUM MERGER II/SH CL AN/AN/A$2.35 millionN/AN/A
Bain Capital Specialty Finance$197.95 million2.70$98.08 million$1.646.30

Bain Capital Specialty Finance has higher revenue and earnings than FORUM MERGER II/SH CL A.

Summary

Bain Capital Specialty Finance beats FORUM MERGER II/SH CL A on 7 of the 10 factors compared between the two stocks.

Global Cord Blood (NYSE:CO) and Bain Capital Specialty Finance (NYSE:BCSF) are both small-cap medical companies, but which is the superior stock? We will contrast the two companies based on the strength of their institutional ownership, dividends, analyst recommendations, profitability, risk, valuation and earnings.

Analyst Ratings

This is a breakdown of current ratings and target prices for Global Cord Blood and Bain Capital Specialty Finance, as provided by MarketBeat.com.

Sell RatingsHold RatingsBuy RatingsStrong Buy RatingsRating Score
Global Cord Blood0000N/A
Bain Capital Specialty Finance16102.00

Bain Capital Specialty Finance has a consensus price target of $12.1429, indicating a potential upside of 17.44%. Given Bain Capital Specialty Finance's higher possible upside, analysts plainly believe Bain Capital Specialty Finance is more favorable than Global Cord Blood.

Volatility & Risk

Global Cord Blood has a beta of 0.36, indicating that its stock price is 64% less volatile than the S&P 500. Comparatively, Bain Capital Specialty Finance has a beta of 1.6, indicating that its stock price is 60% more volatile than the S&P 500.

Institutional & Insider Ownership

15.3% of Global Cord Blood shares are owned by institutional investors. Comparatively, 52.2% of Bain Capital Specialty Finance shares are owned by institutional investors. 0.4% of Bain Capital Specialty Finance shares are owned by company insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a company is poised for long-term growth.

Profitability

This table compares Global Cord Blood and Bain Capital Specialty Finance's net margins, return on equity and return on assets.

Net MarginsReturn on EquityReturn on Assets
Global Cord Blood38.57%12.64%6.72%
Bain Capital Specialty Finance-21.80%8.72%3.26%

Valuation and Earnings

This table compares Global Cord Blood and Bain Capital Specialty Finance's gross revenue, earnings per share and valuation.

Gross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Global Cord Blood$172.50 million2.32$66.48 millionN/AN/A
Bain Capital Specialty Finance$197.95 million2.70$98.08 million$1.646.30

Bain Capital Specialty Finance has higher revenue and earnings than Global Cord Blood.

Summary

Bain Capital Specialty Finance beats Global Cord Blood on 8 of the 12 factors compared between the two stocks.

Competitor NameCompetitor BTM RankCompetitor PriceCompetitor Price ChangeCompetitor Market CapCompetitor RevenueCompetitor P/E RatioCompetitor Indicator(s)
VRRM
Verra Mobility
1.7$9.84+2.1%$1.59 billion$416.72 million42.78
AHCO
AdaptHealth
1.5$18.80+2.4%$889.68 million$529.64 million62.67Analyst Upgrade
Analyst Revision
Heavy News Reporting
GSAH
GS ACQUISITION /SH CL A
0.6$13.88+0.4%$767.63 millionN/A126.19
HYAC
HAYMAKER ACQUIS/SH CL A
0.7$10.56+1.0%$522.49 millionN/A0.00
FMCI
FORUM MERGER II/SH CL A
0.6$16.36+1.8%$412.20 millionN/A0.00
Global Cord Blood logo
CO
Global Cord Blood
0.9$3.29+1.2%$399.90 million$172.50 million5.98
CCAP
Crescent Capital BDC
1.7$12.14+2.1%$341.95 million$53.48 million6.67
GRSH
Gores Holdings III
0.8$9.29+3.2%$339.88 millionN/A0.00
AMCI
Andina Acquisition Corp. III
0.7$10.28+0.3%$257 millionN/A0.00
NFH
New Frontier Health
0.6$8.27+0.4%$238.63 million$354.40 million0.00
ANDA
ANDINA ACQUISIT/SH SH
0.7$10.40+0.9%$145.76 millionN/A0.00High Trading Volume
Heavy News Reporting
AgroFresh Solutions logo
AGFS
AgroFresh Solutions
1.6$2.25+1.8%$115.56 million$170.07 million-2.10
OPES
Opes Acquisition
0.7$13.02+0.8%$102.38 millionN/A-130.20
IEA
Infrastructure and Energy Alternatives
1.2$3.72+4.0%$83.72 million$1.46 billion-5.17Increase in Short Interest
GPAQ
Leisure Acquisition
0.6$12.00+7.1%$79.87 millionN/A-600.00High Trading Volume
HCCH
HL Acquisition
0.7$12.13+4.3%$79.59 millionN/A0.00
AESE
Allied Esports Entertainment
1.6$2.37+5.9%$67.18 million$26.07 million-3.04Heavy News Reporting
TMSR
TMSR
0.4$1.83+1.1%$52.75 million$19.58 million-45.75
KBLM
KBL MERGER CORP/SH
0.6$11.00+0.0%$48.66 millionN/A0.00
WRLS
Pensare Acquisition
0.8$3.15+0.0%$36.10 millionN/A0.00High Trading Volume
DEAC
DIAMOND EAGLE A/SH CL A
1.4$32.80+0.9%$0.00N/A0.00High Trading Volume
This page was last updated on 7/11/2020 by MarketBeat.com Staff

30 Days of MarketBeat All Access for $1.00

Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools:

  • Best-in-Class Portfolio Monitoring

    View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio.

  • Stock Ideas and Recommendations

    Get daily stock ideas top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report.

  • Advanced Stock Screeners and Research Tools

    Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis.

Start Your Risk-Free Trial Subscription Here

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.